NDA 019785 · Shine
Miraluma
Technetium Tc-99m Sestamibi Kit · Injection
NovelLast checked: Nov 20, 2026Latest source record: Dec 4, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Dec 21, 1990
Approved uses
6
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
476
168 serious, 22 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2026.
1. INDICATIONS AND USAGE CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions Myocardial Imaging: CARDIOLITE ® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. CARDIOLITE ® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: MIRALUMA ® , Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. MIRALUMA ® is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.
Mechanism: Technetium Tc99m Sestamibi is a cationic Tc99m complex which has been found to accumulate in viable myocardial tissue in a manner analogous to that of thallous chloride Tl-201. Scintigraphic images obtained in humans after the intravenous administration of the drug have been comparable to those obtained with thallous chloride Tl-201 in normal and abnormal myocardial tissue. Animal studies have shown that myocardial uptake is not blocked when the sodium pump mechanism is inhibited. Although studies of subcellular fractionation and electron micrographic analysis of heart cell aggregates suggest...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2008 Supplement 18 · Efficacy Summary ReviewLabelLetter
- May 23, 1997 Supplement 6 · Efficacy
- Dec 14, 1995 Supplement 4 · Efficacy
- Dec 14, 1995 Supplement 5 · Efficacy
- Sep 9, 1992 Supplement 2 · Efficacy
- Dec 21, 1990 Original approval · Type 1 - New Molecular Entity
2 products under this application
- MIRALUMA · TECHNETIUM TC-99M SESTAMIBI KIT N/A · INJECTABLE, INJECTION · Discontinued
- CARDIOLITE · TECHNETIUM TC-99M SESTAMIBI KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Sestamibi Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective94
- nausea46
- product preparation error39
- rash36
- dyspnoea34
- urticaria32
- dizziness29
- headache27
- chest pain24
- vomiting21
- cough18
- anxiety16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 34 |
| 2005 | 46 |
| 2006 | 37 |
| 2007 | 37 |
| 2008 | 56 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 12 |
| 2012 | 9 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 10 |
| 2016 | 11 |
| 2017 | 20 |
| 2018 | 21 |
| 2019 | 14 |
| 2020 | 8 |
| 2021 | 8 |
| 2022 | 25 |
| 2023 | 15 |
| 2024 | 26 |
| 2025 | 42 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mitochondrial uptake of sestamibi distinguishes between normal, inflammatory breast changes, pre-cancers, and infiltrating breast cancer.
Fleming RM · Integr Cancer Ther 2002 · Clinical Trial
Sponsor: Shine · Also marketed as Cardiolite
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.